According to filings with the U.S. Securities and Exchange Commission, Wheeler Bio is raising $31,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Jesse Mccool played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Wheeler Bio
A disruptive new biopharmaceutical CDMO, we are pushing the boundaries of biomanufacturing and solving an outdated industry bottleneck with a unique partnering model. By bringing together biologics drug innovators, discovery CROs, and CDMOs, we are accelerating the translation of therapeutic innovation to clinical impact. Wheeler Bio brings biologics drug innovators, discovery CROs, and CDMOs together to solve an outdated industry bottleneck with a unique partnering model, built on shared success and lasting collaborations. The typical momentum drop between discovery and development poses significant challenges for emerging biopharma companies adding technical, financial, and regulatory risks. We believe these lifecycle challenges can be reduced with more democratization of manufacturing platforms. Wheeler is proud to currently offer best-in class mammalian cell line development, GLP material supply, and an efficient path to GMP. Connect with our team today to learn more about how Wheeler can add value to your project.

To learn more about Wheeler Bio, visit http://www.wheelerbio.com/

Contact:
Jesse Mccool, Chief Executive Officer
405-279-6767
https://www.linkedin.com/in/jessemccool/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.